Roy, Rajarshi

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial

Hall, P. S., Swinson, D., Waters, J. S., Wadsley, J., Falk, S., Roy, R., Tillett, T., Nicoll, J., Cummings, S., Grumett, S. A., et al. (2019) · Journal of Clinical Oncology

Frailty in Older AdultsGastric Cancer Management and Outcomes

Cited by 59